SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 193.87+2.5%12:20 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (3373)6/6/1997 9:43:00 AM
From: Henry Niman   of 32384
 
Here's a summary of a National Cancer Institute journal article showing a synergistic effect between Panretin and Raloxifene. Of course LGND has many additional retinoids (Targretin and ALRT1550 are in patients and 2 or 3 more are slated to begin trials next year) and its collaborations with PFE and AHP target anti-estrogens (Droloxifene is in advanced clinical trials for breast cancer and osteoporosis and CP366,156 was slated to enter the clinic last year for the treatment of osteoporosis):

Breast Cancer Chemoprevention

In a brief communication, Anzano et al. (p. 123) report that raloxifene and 9-cis-retinoic acid
(9cRA) generated statistically significant reductions in mammary carcinogenesis in rats. 9cRA is a
chemopreventive agent. Raloxifene, an estrogen response modifier, was investigated for
chemopreventive activity because it does not promote uterine epithelial growth, a concern with
long-term use of tamoxifen, which has been shown to increase risk of endometrial cancer, the
investigators say.

The investigators induced breast tumors by injecting nitrosomethylurea intravenously into 264 virgin
female Sprague-Dawley rats, which were randomly selected to receive raloxifene (60 or 20 mg/kg
diet) and/or 9cRA (60 mg/kg diet) or no treatment.

Rats fed high or low doses of raloxifene had statistically significant reductions in the incidence and
weight of breast tumors, compared with controls. The addition of 9cRA to the regimens significantly
reduced tumor incidence and weight even further. Also, these agents were not toxic at the levels
studied.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News